98%
921
2 minutes
20
Importance: Vasa previa, although a rare condition affecting 0.46 per 1000 pregnancies, results in high rates of fetal and neonatal mortality and morbidity. Widespread use of a core outcome set and reporting checklist may enable data harmonization, enhance evidence synthesis, and ensure prioritization of patient-important outcomes in clinical practice, future research, and clinical practice guidelines.
Objective: To develop a core outcome set for studies on vasa previa that includes perinatal screening, diagnosis, and management of vasa previa.
Design, Setting, And Participants: This survey study involved a 2-round international and cross-disciplinary Delphi survey and virtual consensus meetings conducted between March 14, 2021, and October 4, 2022. Health care professionals (HCPs) and health service users (HSUs) were invited to participate in the development of the core outcome set.
Exposure: Perinatal screening, diagnosis, and management of vasa previa.
Main Outcome And Measures: Core outcomes and reporting checklist items for future studies on vasa previa were developed using Delphi surveys, small group discussions, and a consensus meeting.
Results: An international group of 204 participants, comprising 115 HSUs and 89 HCPs representing 27 countries, rated 67 outcomes identified through a systematic review and qualitative interviews in a 2-round online Delphi survey. Through virtual small group discussions and a consensus meeting, 13 core outcomes were identified: pregnancy outcome (live birth, fetal loss [miscarriage or stillbirth], or neonatal death), severe neonatal morbidity, fetal/neonatal blood loss, neonatal intensive care unit admission for >24 hours, gestational age at birth, third trimester confirmation of vasa previa diagnosis, neurocognitive and developmental outcomes, mode of birth, maternal death or severe morbidity, maternal quality of life, duration of antepartum admission, and antepartum or peripartum hemorrhage. A 22-item reporting checklist was simultaneously developed to include important items in studies on vasa previa when possible and/or relevant.
Conclusions And Relevance: The core outcome set and reporting checklist for vasa previa are hoped to encourage researchers to incorporate patient-important outcomes in future studies to enable data harmonization, improve evidence synthesis, and facilitate the development of clinical practice guidelines for this rare and highly lethal condition for which timely diagnosis and management may prevent fetal and maternal morbidity and mortality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920838 | PMC |
http://dx.doi.org/10.1001/jamanetworkopen.2025.1000 | DOI Listing |
Am J Obstet Gynecol
August 2025
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Fetal Care and Surgery Center (FCSC), Division of Maternal-Fetal Medicine and Surgery, Boston Children's Hospital, Boston, MA,
Objective: To evaluate the prenatal detection of vasa previa (VP) and perinatal survival in studies that implemented standardized protocols of prospective second-trimester ultrasound screening protocols followed by ultrasound confirmation in the third trimester.
Data Sources: PubMed/MEDLINE, Web of Science, EMBASE, Global Health, and Global Index Medicus were searched from inception to February 16, 2024.
Study Eligibility: We included cohort studies that implemented standardized second-trimester ultrasound protocols - either universal or targeted - for VP screening, with third-trimester ultrasound confirmation and verification at delivery, over at least one year.
Magn Reson Med Sci
August 2025
Department of Diagnostic Radiology, Tohoku University Hospital, Sendai Miyagi, Japan.
The umbilical cord and placenta, classified as fetal appendages, play a crucial role in fetal growth and survival. While ultrasonography remains the primary modality for evaluation, MRI provides a more objective and comprehensive assessment, particularly for the placenta and fetus. Although MRI assessment of the umbilical cord is still emerging and not yet widely adopted by radiologists, MRI has the potential to support and complement ultrasound findings, thereby contributing to safer perinatal management.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
July 2025
Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Shimotsuke, Tochigi 329-0498, Japan.
Objective: To clarify whether the maternal backgrounds and perinatal outcomes of the three types of vasa previa (VP) differ based on placental location and cord insertion.
Methods: A retrospective questionnaire survey of VP cases in all 408 perinatal centers in Japan was conducted. The survey covered the clinical information of VP cases, including maternal characteristics, prenatal management, and perinatal outcomes, between January 2020 and December 2022.
Eur J Obstet Gynecol Reprod Biol
August 2025
Amsterdam University Medical Centers, Department of Obstetrics, Meibergdreef 9, P.O. box 22660, 1100 DD Amsterdam, the Netherlands.
Objectives: To quantify the risk of intrauterine fetal death (IUFD) associated with isolated velamentous cord insertion (VCI) and identify subgroups at increased risk to guide clinical management.
Methods: We conducted a retrospective case-control study and a systematic review with meta-analysis. The case-control study included singleton pregnancies with VCI and no fetal anomalies diagnosed at Amsterdam UMC (2007-2024), matched 1:2 to controls without VCI or anomalies, based on year of detection and scan type.
Taiwan J Obstet Gynecol
July 2025
Department of Fetal Medicine, Taiji Clinic, Taipei, Taiwan. Electronic address: